Andersch B, Hahn L
Pharmatherapeutica. 1982;3(2):107-13.
Thirty-four patients suffering from the premenstrual syndrome were studied during 5 consecutive menstrual cycles. After a control cycle, bromocriptine and placebo were given during the luteal phase of the cycle in a random, double-blind manner, each patient serving as her own control. Bromocriptine (1.25 mg twice daily) was given for 3 cycles and placebo for 1 cycle. Serum prolactin levels were within normal limits without treatment and were significantly reduced by bromocriptine. Serum progesterone did not change during treatment. Medication considerably improved all the premenstrual symptoms but bromocriptine was not significantly better than placebo. These results do not support the hypothesis that prolactin alone causes premenstrual symptoms.
对34名患有经前综合征的患者进行了连续5个月经周期的研究。在一个对照周期后，在周期的黄体期以随机、双盲的方式给予溴隐亭和安慰剂，每位患者作为自身对照。溴隐亭（每日两次，每次1.25毫克）给药3个周期，安慰剂给药1个周期。未经治疗时血清催乳素水平在正常范围内，溴隐亭使其显著降低。治疗期间血清孕酮未发生变化。药物治疗使所有经前症状均有显著改善，但溴隐亭并不比安慰剂有明显更好的效果。这些结果不支持仅催乳素导致经前症状的假说。
